CD39 [EPR20627]
$327.00 – $1,303.00
Description
Product Description
CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), can hydrolyze extracellular ATP and ADP. It is one of the key enzymes in the adenosine pathway and targeted adenosine may play a role in antitumor strategies.15 CD39 pathway inhibits natural killer (NK) cells and promotes the metastasis of tumors.15 Overexpression of CD39 has been observed in many human cancer types such as melanoma, leukemia, pancreatic cancer, colon cancer, and ovarian cancer.16 Determining the level of CD39 expression may indicate cancer virulence and may aid with anticancer treatment strategies.16,17
Specifications
Specifications
| Intended Use | |
|---|---|
| Format | |
| Volume | |
| Source | |
| Species Reactivity | |
| Clone | |
| Isotype | |
| Localization |
Datasheet & SDS
| Download Data Sheet |
| Download RUO Data Sheet |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
References
1. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
2. Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. 1980.
3. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
4. Shi S-R, Cote RJ, Taylor CR. J Histotechnol. 1999 Sep;22(3):177-92.
5. Taylor CR, et al. Biotech Histochem. 1996 Jan;71(5):263-70.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
8. CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011
9. College of American Pathologists (CAP) Certification Program for Immunohistochemistry. Northfield IL. Http://www.cap.org (800) 323- 4040.
10. O’Leary TJ, Edmonds P, Floyd AD, Mesa-Tejada R, Robinowitz M, Takes PA, Taylor CR. Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA. 1997;1-46.
11. Koretzik K, Lemain ET, Brandt I, and Moller P. Metachromasia of 3- amino-9-ethylcarbazole (AEC) and its prevention in Immunoperoxidase techniques. Histochemistry 1987; 86:471-478.
12. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983; 14:767.
13. Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a possible source of error in immunohistochemistry. AmJ Clin Path 1980; 73:626.
14. Herman GE and Elfont EA. The taming of immunohistochemistry: the new era of quality control. Biotech & Histochem 1991; 66:194.
15. Chen S, Wu S, Zhang L, et al. CD39: the potential target in small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):1483-1495.
16. Timperi E, Barnaba V. CD39 Regulation and Functions in T Cells. Int J Mol Sci. 2021;22(15):8068. Published 2021 Jul 28.
17. Cai XY, Ni XC, Yi Y, et al. Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection. Medicine (Baltimore). 2016 Oct;95(40): e4989.
